CD19 and lobular neoplasia: Another pilot trial indicated that BCMA-CD19 CAR-T therapy in 13 patients with SLE or LN could eliminate autoantibodies, reset the B cell and humoral immune systems, and provide long-term, medication-free remission with a single dose (149).